Rareview Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Rareview Capital's XBI Position: Q1 2025 in Review
Rareview Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 4,154 shares — an estimated $410K sold.
Rareview Capital first reported a position in XBI in Q1 2024 and held it in 4 quarters. The position peaked at $453K in Q3 2024. 685 funds tracked by Wall St. Rank hold XBI as of Q1 2025.
- Rareview Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
- Rareview Capital sold 4,154 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $410K.
- Rareview Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and held it in 4 quarters.
- Rareview Capital's State Street SPDR S&P Biotech ETF position peaked at $453K in Q3 2024.
- 685 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.
Based on Rareview Capital's 13F filing for Q1 2025, filed 7 May 2025.